Utilization characteristics and treatment persistence in patients prescribed low-dose buprenorphine patches in primary care in the United Kingdom: A retrospective cohort study

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1707-1715

  Gallagher, Arlene M ^a   Leighton Scott, James ^b   van Staa, Tjeerd P ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^b Mundipharma Research Ltd   (United Kingdom)

Author keywords

buprenorphine; codeine; osteoarthritis; pain; tramadol; transdermal

Indexed keywords

BUPRENORPHINE; CODEINE; DIHYDROCODEINE; TRAMADOL;

ADULT; AGED; ARTICLE; BACKACHE; CANCER PAIN; CHRONIC PAIN; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DRUG UTILIZATION; FEMALE; GENERAL PRACTICE; HUMAN; LOCAL SKIN REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PATIENT ASSESSMENT; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED KINGDOM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC DISEASE; CODEINE; COHORT STUDIES; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PAIN; PRIMARY HEALTH CARE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TRAMADOL; YOUNG ADULT;

EID: 72149083861     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.022     Document Type: Article

References (32)

1. Mundipharma International Limited. Pain in Europe: A report. http://www.paineurope.com/index.php?q=en/book_page/the_pain_in_europe_report/ Accessed August 3, 2009
2. International Association for the Study of Pain, and Subcommittee on Taxonomy. Classification of chronic pain. Descriptions of chronic pain syndromes and definitions of pain terms. Pain 3 (1986) S1-S226
3. OA nation: The most comprehensive UK report of people with osteoarthritis (2004), Arthritis Care/Napp Pharmaceuticals Limited, London, UK
4. Arthritis Research Campaign. Arthritis: The big picture. http://www.arc.org.uk/arthinfo/documents/BigPic.pdf Accessed September 1, 2008
5. Brown T.J., Hooper L., Elliott R.A., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modelling. Health Technol Assess. 10 (2006) iii-iv
6. Brown T.J., Hooper L., Elliott R.A., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modelling. Health Technol Assess. 10 (2006) xi-xiii
7. Brown T.J., Hooper L., Elliott R.A., et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modelling. Health Technol Assess. 10 (2006) 1-183
8. Hippisley-Cox J., Coupland C., and Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ. 331 (2005) 1310-1316
9. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet 369 (2007) 1621-1626
10. Avouac J., Gossec L., and Dougados M. Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 15 (2007) 957-965
11. Kalso E., Edwards J.E., Moore R.A., and McQuay H.J. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 112 (2004) 372-380
12. Spyker D.A., Hale M.E., Karpow S.E., et al. Effectiveness of buprenorphine transdermal system (BTDS) compared with oxycodone/acetaminophen and placebo in the treatment of patients with chronic back pain. Anesthesiology. 95 (2001) A826 Abstract
13. Spyker D., Hale M., Munera C., and Wright C. Effectiveness and safety of buprenorphine transdermal system (BTDS) compared with hydrocodone/acetaminophen in the treatment of patients with chronic low back pain. J Pain 3 Suppl 1 (2002) 14 Abstract 653
14. Landau C.J., Carr W.D., Razzetti A.J., et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: A multi-center, 5-week run-in and randomized, double-blind maintenance-of-analgesia study [published correction appears in Clin Ther. 2009;31:677]. Clin Ther. 29 (2007) 2179-2193
15. Spyker D.A., Hale M.E., Lederman M., et al. Long-term use of buprenor-phine transdermal system (BTDS) in patients with chronic pain. J Am Geriatr Soc. 50 Suppl 4 (2002) S66 Abstract
16. Schutter U., Ritzdorf I., and Heckes B. Treatment of chronic osteoarthritis pain: Effectivity and safety of a 7 day matrix patch with a low dose buprenorphine [in German]. MMW Fortschr Med. 150 Suppl 2 (2008) 96-103
17. Foley K.M. The treatment of cancer pain. N EnglJ Med. 313 (1985) 84-95
18. Twycross R., and Wilcock A. Palliative Care Formulary. 3rd ed (2007), Palliativedrugs.com Ltd, Nottingham, UK
19. Walley T., and Mantgani A. The UK General Practice Research Database. Lancet 350 (1997) 1097-1099
20. Clayton D., and Hills M. Statistical Models in Epidemiology (1993), Oxford University Press, New York, NY
21. BuTrans transdermal patches [package insert] (2009), Napp Pharmaceuticals Limited, Cambridge, UK
22. Sackett D.L., and Snow J.C. The magnitude of compliance and non-compliance. In: Sackett D.L., and Haynes R.B. (Eds). Compliance With Therapeutic Regimens (1976), Johns Hopkins University Press, Baltimore, Md 9-25
23. DiMatteo M.R. Enhancing patient adherence to medical recommendations. JAMA. 271 (1994) 79-83
24. Berg J.S., Dischler J., Wagner D.J., et al. Medication compliance: A healthcare problem. Ann Pharmacother. 27 Suppl 9 (1993) S1-S24
25. Morris L.S., and Schulz R.M. Patient compliance-an overview. J Clin Pharm Ther. 17 (1992) 283-295
26. Haynes R.B., McKibbon K.A., and Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications [published correction appears in Lancet. 1997;349:1180]. Lancet 348 (1996) 383-386
27. Donovan J.L., and Blake D.R. Patient non-compliance: Deviance or reasoned decision-making?. Soc Sci Med. 34 (1992) 507-513
28. Conaghan P.G., Schofield J.P., and O'Brien C. A head-to-head comparison of BuTrans/Norspan (buprenorphine transdermal patches) versus co-codamol in elderly patients with severe hip and knee osteoarthritis. Presented at: EULAR 2008. Paris, France (June 11-14, 2008) Poster THU0300
29. Karlsson M., and Berggren A.C. Efficacy and safety of low-dose transdermal buprenorphine patches (5, 10, and 20 microg/h) versus prolonged- release tramadol tablets (75, 100, 150, and 200 mg) in patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallel-group noninferiority study. Clin Ther. 31 (2009) 503-513
30. Alvarez-Requejo A., Carvajal A., Bégaud B., et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 54 (1998) 483-488
31. Moride Y., Haramburu F., Requejo A.A., and Bégaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol. 43 (1997) 177-181
32. van Riemsdijk M.M., Herings R.M., Rawlins M.D., and Stricker B.H. Reasons to report or not report side effects of drugs to the national monitoring system in the Netherlands [in Dutch]. Ned Tijdschr Geneeskd. 139 (1995) 2306-2308